Episode One APPROVED.mp3

Transcript

00:00:00 Jenn Dawson

Hello and welcome to PeDRA Pearls, the podcast from the Pediatric Dermatology Research Alliance.

00:00:06 Jenn Dawson

We are a vibrant research community pursuing a mission to create, inspire, and sustain research to prevent, treat, and cure childhood skin disease.

00:00:16 Jenn Dawson

Each week, we bring you inspiring stories, research updates, and practical information to advance science that improves the lives of children with skin diseases and conditions.

00:00:27 Jenn Dawson

I'm Jenn Dawson, host of PeDRA Pearls and PeDRA’s Director of Educational Programs.

00:00:33 Jenn Dawson

I'm so glad you're here.

00:00:39 Jenn Dawson

Before we jump into our episode, just a quick note.

00:00:42 Jenn Dawson

Full disclaimers will be provided at the conclusion of the episode, and further information along with relevant links are available in the episode notes.

00:00:50 Jenn Dawson

Today is the first episode in a three-part series exploring the world of clinical trials.

00:00:56 Jenn Dawson

In this conversation, our expert panel breaks down what makes academic clinical research unique, why clinical trials matter, and how studies move from idea to a fully executed protocol.

00:01:08 Jenn Dawson

You'll hear insights

00:01:09 Jenn Dawson

to the roles of sponsors, CROs, IRBs, investigators, and research terms, along with the advantages and challenges of conducting trials in academic versus non-academic settings.

00:01:21 Jenn Dawson

I'd like to introduce your host and moderator for the next three episodes, Dr.

00:01:26 Jenn Dawson

Thy

00:01:26 Jenn Dawson

Huynh.

00:01:27 Jenn Dawson

Dr.

00:01:27 Jenn Dawson

Huynh is a pediatric dermatologist and an assistant professor in both dermatology and pediatrics at the University of Mississippi Medical Center.

00:01:36 Jenn Dawson

She is also the director of clinical trials in dermatology.

00:01:40 Jenn Dawson

So thank you so much for stepping into the host seat.

00:01:43 Jenn Dawson

Dr.

00:01:44 Jenn Dawson

Huynh, I'll turn it over to you.

00:01:46 Dr. Huynh

Thank you, Jenn.

00:01:47 Dr. Huynh

Joining me is Dr.

00:01:48 Dr. Huynh

Jason Hawkes and Dr.

00:01:49 Dr. Huynh

Jeff Sugarman.

00:01:51 Dr. Huynh

I'll give them a chance to introduce themselves and briefly summarize their clinical trials experience.

00:01:56 Dr. Huynh

Dr.

00:01:57 Dr. Huynh

Hawkes, why don't you get started?

00:01:58 Jenn Dawson

Yeah, thanks for having me.

00:02:00 Dr. Hawkes

I'm Dr.

00:02:00 Dr. Hawkes

Jason Hawkes.

00:02:01 Dr. Hawkes

I'm a board-certified dermatologist.

00:02:04 Dr. Hawkes

and the co-owner and chief scientific officer and investigator at the Oregon Medical Research Center in Portland, Oregon, where we primarily run clinical trials.

00:02:13 Dr. Hawkes

We run about 40 clinical trials at any given time.

00:02:16 Dr. Hawkes

And previously to this, spent most of my time in academic dermatology and excited to be here and have this fun discussion.

00:02:24 Dr. Huynh

Dr.

00:02:25 Dr. Huynh

Jeff Sugerman.

00:02:26 Dr. Sugarman

Thank you so much for having me.

00:02:27 Dr. Sugarman

I am a board-certified pediatric dermatologist.

00:02:31 Dr. Sugarman

I'm the medical director at Redwood Family Dermatology, which is a fairly large multi-specialty dermatology practice in the Bay Area.

00:02:40 Dr. Sugarman

I participated in over 100 clinical trials as both a principal investigator and as a medical monitor.

00:02:48 Dr. Sugarman

I'm also a volunteer clinical professor at UC San Francisco in the Department of Dermatology and Family Medicine.

00:02:54 Dr. Huynh

Welcome, welcome.

00:02:54 Dr. Huynh

We're going to spend the next three episodes talking about clinical trials, and we'll hopefully pick up some pearls, learn how to avoid common pitfalls along the way.

00:03:04 Dr. Huynh

Let's focus on what makes academic clinical research unique and why it matters.

00:03:11 Dr. Huynh

So, Dr.

00:03:11 Dr. Huynh

Hawkes, what defines an academic clinical trial to you?

00:03:15 Dr. Hawkes

You know, I wouldn't traditionally put academic before a clinical trial because I think academic kind of communicates the

00:03:23 Dr. Hawkes

clinical trial occurring at a particular location.

00:03:26 Dr. Hawkes

But a clinical trial is, to me, really the chance where we get to apply the same rigors of science to medications and patients.

00:03:35 Dr. Hawkes

So for those of us that have spent time in laboratory benchtop research, we're using artificial systems.

00:03:42 Dr. Hawkes

But the clinical trials are a formal way.

00:03:45 Dr. Hawkes

that's organized to actually test therapies or test ideas in humans with specific diseases.

00:03:53 Dr. Hawkes

And these can occur, obviously, in academic centers, but also in private clinics or even healthcare systems.

00:04:01 Dr. Hawkes

And this gives us a chance to get objective evidence so that we can inform the

00:04:07 Dr. Hawkes

the decisions we are going to make with regards to treatment, but also it's the basis for decisions that patients can make as to choosing therapy A over B versus C.

00:04:18 Dr. Sugarman

Just to dovetail on what Jason just said, many clinical trials actually have sites in academic centers as well as in private practice.

00:04:28 Dr. Sugarman

So you can have one trial with both.

00:04:31 Dr. Sugarman

academic and non-academic sites participating.

00:04:35 Dr. Sugarman

And in fact, in my experience, many clinical trials are set up that way.

00:04:39 Dr. Huynh

And Dr.

00:04:40 Dr. Huynh

Sugarman, how do you find that these studies become initiated?

00:04:43 Dr. Huynh

What's the starting process?

00:04:46 Dr. Sugarman

The first thing that happens really is that the sponsor of the trial has to hire, usually, a CRO or clinical research organization to help them run the trial.

00:04:59 Dr. Sugarman

So usually a sponsor isn't doing that themselves, but it's better if they have sort of an arm's length distance from the trial, so there's not a perception of bias from the sponsor.

00:05:12 Dr. Sugarman

So if you have a pharmaceutical company, A, for example, and they're running the trial and making decisions, you know, about who's, you know, doing what, there may be a sense that they're manipulating

00:05:27 Dr. Sugarman

things.

00:05:27 Dr. Sugarman

And so the standard these days is to have a middle body, a clinical research organization or CRO, that actually runs the trial.

00:05:37 Dr. Huynh

And how are these trials funded and reviewed in the academic settings?

00:05:42 Dr. Huynh

Dr.

00:05:42 Dr. Huynh

Hawks, can you give us some viewpoints on that?

00:05:45 Dr. Hawkes

Yeah, and Jeff's...

00:05:47 Dr. Hawkes

you know, introduced the, what we see is the traditional trial mechanism where most of these are actually sponsored or funded by pharmaceutical companies or even early startup companies.

00:05:59 Dr. Hawkes

But there are other mechanisms as well, which gets to sort of the, you know, how they're set up and sort of how they work.

00:06:07 Dr. Hawkes

But we have investigator-initiated studies.

00:06:10 Dr. Hawkes

These are studies that, you know,

00:06:12 Dr. Hawkes

Dr.

00:06:13 Dr. Hawkes

Sugarman or myself could say, hey, I have an idea and I want to design a study and test in patients and run it at a site.

00:06:19 Dr. Hawkes

We could do that with a small group, a collaborative group of sites.

00:06:24 Dr. Hawkes

And you can also do studies that don't have interventions.

00:06:28 Dr. Hawkes

So that could be simply observing a natural phenomenon.

00:06:31 Dr. Hawkes

So those are funded in different ways.

00:06:34 Dr. Hawkes

Those might be funded by academic centers or research organizations like PGO or the National Psoriasis Foundation, for example.

00:06:42 Dr. Hawkes

But once the trials get set up, once they're funded, it's, you know, following a recipe.

00:06:51 Dr. Hawkes

I always talk to our patients as

00:06:53 Dr. Hawkes

of a recipe for what the study looks like.

00:06:56 Dr. Hawkes

And we all try to follow that same protocol.

00:06:59 Dr. Hawkes

And that helps keep consistency across sites.

00:07:02 Dr. Hawkes

It helps have predetermined measures in a clinical trial so that you don't run the risk of a group not getting the result they wanted and trying to change after the fact.

00:07:15 Dr. Hawkes

So it gives you the transparency, the honesty,

00:07:20 Dr. Hawkes

These usually result in publications, most of the time for positive trials, but occasionally in negative trials where maybe a particular therapy didn't work.

00:07:29 Dr. Hawkes

And that's also informative to a clinician making a decision about a therapy when they have other options.

00:07:35 Dr. Hawkes

So these are sort of some of the ways that after the funding, the process of the trials, you know, get conducted and go on.

00:07:44 Dr. Huynh

So Dr.

00:07:44 Dr. Huynh

Hawks, can you give me an example of what some of these recipes would look like?

00:07:50 Dr. Hawkes

So a good example, if we take, let's say, psoriasis, for example, in the study protocol, there's criteria that these patients need to meet in order to qualify for the study.

00:08:01 Dr. Hawkes

We call those the inclusion criteria.

00:08:04 Dr. Hawkes

And then there are exclusion criteria, which are criteria that they can't have or excludes them from the study.

00:08:11 Dr. Hawkes

Before the trial starts and is designed, we're setting up those criteria so we know what's the study population we're looking at.

00:08:18 Dr. Hawkes

Is this kids?

00:08:19 Dr. Hawkes

Is this adolescents?

00:08:20 Dr. Hawkes

Is this adults?

00:08:20 Dr. Hawkes

Is it a combination?

00:08:22 Dr. Hawkes

Is this an interventional trial?

00:08:24 Dr. Hawkes

Is this a trial where we're giving a therapy or are we comparing it to placebo, for example?

00:08:31 Dr. Hawkes

And is it multicenter?

00:08:33 Dr. Hawkes

Does it involve multiple sites?

00:08:36 Dr. Hawkes

So the protocol is predetermined, it's approved.

00:08:39 Dr. Hawkes

usually by a regulatory body, so like here in the US, like the FDA.

00:08:44 Dr. Hawkes

And that's going to be the approved set of rules, if you want to think of it that way.

00:08:49 Dr. Hawkes

That's going to determine how the study is conducted, but also how we handle things like adverse events or side effects or prohibited medications.

00:08:58 Dr. Hawkes

Some people get sick, some people need surgery or have accidents.

00:09:01 Dr. Hawkes

So this is really the book that we can follow throughout the study, and it keeps all of us on the same page.

00:09:08 Dr. Huynh

Thank you.

00:09:08 Dr. Huynh

So I'd like to kind of highlight some things.

00:09:11 Dr. Huynh

You know, you mentioned a very controlled setting, and as a principal investigator to run a clinical trial, you would definitely need a seasoned team.

00:09:22 Dr. Huynh

Dr.

00:09:22 Dr. Huynh

Sugarman, can we discuss some of the team establishments, such as the research coordinator, a regulatory specialist, and even maybe what the role of a medical student would be on a clinical trial?

00:09:35 Dr. Sugarman

Probably the most important person at your site is going to be your study coordinator.

00:09:41 Dr. Sugarman

And in large sites like Jason's, Dr.

00:09:43 Dr. Sugarman

Hawk's site, there are going to be multiple study coordinators because a study coordinator can really only handle two or three studies at a time.

00:09:52 Dr. Sugarman

That's the person that really is going to know the protocol inside out.

00:09:56 Dr. Sugarman

He or she will be responsible for helping with recruiting and making sure that

00:10:01 Dr. Sugarman

the refrigerators are working correctly and that, all those little details are happening.

00:10:07 Dr. Sugarman

And so without a really good study coordinator, it's really almost impossible to run a good clinical trial.

00:10:13 Dr. Sugarman

And so, they'll make or break you basically is what we say in the industry.

00:10:18 Dr. Sugarman

So that's the main, the most important sort of central person.

00:10:23 Dr. Sugarman

The principal investigator would be someone like Dr.

00:10:25 Dr. Sugarman

Hawks or myself.

00:10:27 Dr. Sugarman

You might have a busy site with sub-investigators, and that can be another physician or dermatologist or a mid-level, even a nurse practitioner or a physician assistant.

00:10:37 Dr. Sugarman

Then you might have other assistants that help with the trial, like that aren't going to be blinded.

00:10:45 Dr. Sugarman

For example, you know, sometimes the way the study medicine is dispensed

00:10:50 Dr. Sugarman

There are some people that are going to have to be completely blinded and there are other assistants that may not be, but might not, you know, be in that case, in that case, they wouldn't be exposed to the study subject.

00:11:03 Dr. Sugarman

But so you're going to need ancillator personnel behind the study coordinator as well.

00:11:08 Dr. Hawkes

Dr.

00:11:08 Dr. Hawkes

Sherman's right on that the study coordinator has to be your source of all information.

00:11:15 Dr. Hawkes

These protocols can be

00:11:17 Dr. Hawkes

150 to 200 pages.

00:11:19 Dr. Hawkes

There's a lot of detail and you need someone to really know the ins and out of that.

00:11:24 Dr. Hawkes

And in addition to some of the people mentioned, we have a full nursing staff.

00:11:28 Dr. Hawkes

We have a phlebotomist.

00:11:30 Dr. Hawkes

So we have someone to draw blood.

00:11:32 Dr. Hawkes

Most of these study visits that usually occur most frequently about every four weeks requires blood draws.

00:11:38 Dr. Hawkes

Sometimes they have biopsies or, you know, tape strip testing when they're trying to do exploratory

00:11:46 Dr. Hawkes

research to try to discover new biomarkers or things that indicate aspects of the disease that will help clinicians.

00:11:54 Dr. Hawkes

We have front office staff to help with coordinating schedules and payments.

00:11:58 Dr. Hawkes

Most of the trial patients get paid, so we have mechanisms in the budget to pay these subjects.

00:12:05 Dr. Hawkes

And we have regulatory and financial individuals that help us.

00:12:10 Dr. Hawkes

The regulatory individuals probably right up there with our

00:12:15 Dr. Hawkes

also most important person because they're responsible for getting approval from the study.

00:12:22 Dr. Hawkes

We have to submit to an IRB, which is an independent group that monitors safety and ethical practices in clinical trials.

00:12:30 Dr. Hawkes

And most of the documentation we have also can be reviewed or even audited by the FDA.

00:12:36 Dr. Hawkes

So this kind of highlights the complexity of running trials.

00:12:40 Dr. Hawkes

It's

00:12:40 Dr. Hawkes

Probably there's a similar complexity to running a clinic.

00:12:44 Dr. Hawkes

You've got a lot of moving parts.

00:12:46 Dr. Hawkes

Teams have to work together and we're governed by a set of rules that are bigger than us as individual sites.

00:12:54 Dr. Hawkes

But doing so and bringing all these pieces together provides a mechanism

00:13:00 Dr. Hawkes

where patients can access care differently than our traditional system, where our healthcare system can be convoluted, it can take time, it can be expensive.

00:13:11 Dr. Hawkes

Waiting to see a specialist, if you have a specialist at an academic center, for example, could take six or nine months.

00:13:18 Dr. Hawkes

And some of these patients, even when they get to these specialized centers, can't always afford medications.

00:13:25 Dr. Hawkes

One of the big advantages to the system working together well at multiple places across the world is these patients can get access to very good therapies, very safe therapies at no cost and get paid for their visits and at the same time contribute to research.

00:13:43 Dr. Hawkes

So it's very important to view this as a mechanism of healthcare delivery that should be complementary

00:13:50 Dr. Hawkes

to academic centers or outpatient clinics.

00:13:53 Dr. Hawkes

This is another way of extending care to the greater population who might have some of these bothersome chronic conditions.

00:14:01 Dr. Huynh

You've touched on a few points of the advantages of running clinical trials in an academic center.

00:14:07 Dr. Huynh

You know, certainly the transparency is there and the role of collaboration with the multicenter sites and scientific independence.

00:14:17 Dr. Huynh

Are there other advantages, would you say, that was there?

00:14:20 Dr. Huynh

Dr.

00:14:21 Dr. Huynh

Sugerman, do you have any comments on some of the advantages?

00:14:24 Dr. Sugarman

I mean, there's advantages and disadvantages in both systems, really.

00:14:28 Dr. Sugarman

Dr.

00:14:28 Dr. Sugarman

Hawkes mentioned the IRB, or Institutional Review Board.

00:14:32 Dr. Sugarman

So that's one aspect of a clinical trial that's going to be different in academia versus in non-academia.

00:14:39 Dr. Sugarman

Most academic centers have their own IRB.

00:14:43 Dr. Sugarman

And the non-academic centers have what's called a central IRB.

00:14:49 Dr. Sugarman

So it's a centralized IRB that multiple different sites can use.

00:14:54 Dr. Sugarman

It's much more efficient.

00:14:57 Dr. Sugarman

And usually the non-academic sites, for that reason, can get up and running for their clinical trial more quickly.

00:15:05 Dr. Sugarman

And in fact, academic centers sometimes complain

00:15:08 Dr. Sugarman

that a lot of subjects have already been enrolled by the time their site's IRB has approved the study, the study's almost closed.

00:15:17 Dr. Sugarman

And so that can be an issue because different academic centers feel like their IRB is the only IRB that can be used, and that's the IRB they trust.

00:15:28 Dr. Sugarman

And there's been a lot of conversation among

00:15:33 Dr. Sugarman

people at Pedra and other clinical researchers to try to loosen that up a little bit so academic centers can also use a central IRB.

00:15:43 Dr. Sugarman

It'll just make, it'll streamline the enrollment process greatly.

00:15:49 Dr. Sugarman

So that's one difference between doing a study in academia versus non.

00:15:54 Dr. Sugarman

There's probably more red tape in academia as well.

00:16:00 Dr. Sugarman

there's just a lot more scrutiny in terms of OSHA and CLIA.

00:16:03 Dr. Sugarman

I mean, everybody has to follow the same rules, but there are basic sets of rules that are set out.

00:16:08 Dr. Sugarman

And then there's institutional rules on top of those.

00:16:12 Dr. Sugarman

And every academic center has their own set of rules.

00:16:15 Dr. Sugarman

And sometimes they can be more onerous and time consuming than the general set of rules.

00:16:21 Dr. Huynh

And you've definitely touched on the challenges with the slower timelines and administrative complexities.

00:16:27 Dr. Huynh

I will throw a comment that my institution has both central as well as local.

00:16:33 Dr. Huynh

So then they throw in both because they wanted to negotiate that to feel like there are choices.

00:16:39 Dr. Huynh

But those are definitely things that are kind of cumbersome in this process.

00:16:45 Dr. Huynh

As these processes evolve, is the conversation shifting from

00:16:49 Dr. Huynh

setting specific differences to a broader emphasis on evidence generation and patient impact.

00:16:55 Dr. Hawkes

Clinical trial becomes, sets the standard for human evidence in making decisions.

00:17:02 Dr. Hawkes

I think that's, it's not the academic at all.

00:17:05 Dr. Hawkes

It's just that academics, you know, for many years sort of led this charge and

00:17:11 Dr. Hawkes

Now it's become privatized and more widespread and more readily available with central IRBs, et cetera, ending it.

00:17:18 Dr. Hawkes

I'd probably try to focus on that, it's changing, but not that one's better versus the other.

00:17:24 Dr. Sugarman

That's actually an important point because the way I said it, made it seem like it was a one or the other, and that's how it's been, but there's already change afoot.

00:17:33 Dr. Sugarman

So it's great to hear that there's some institutions that have both.

00:17:36 Dr. Huynh

Thank you for this great conversation, and I'm looking forward to learning more in our next episode.

00:17:41 Jenn Dawson

Thank you so much to Dr.

00:17:42 Jenn Dawson

Huynhand Dr.

00:17:43 Jenn Dawson

Hawks and Dr.

00:17:44 Jenn Dawson

Sugarman for participating in this episode.

00:17:48 Jenn Dawson

In this episode, we unpacked the core elements of clinical trials, from how studies are initiated and funded to how protocols are designed to ensure scientific rigor, transparency, and consistency across sites.

00:18:00 Jenn Dawson

Our speakers highlighted the critical roles played by study coordinators, investigators, regulatory specialists, and supporting staff in bringing a trial to life.

00:18:10 Jenn Dawson

We also explored the unique strengths and hurdles of academic centers, including regulatory complexities, IRB structures, and collaboration across multiple sites.

00:18:21 Jenn Dawson

Ultimately, clinical trials, whether academic or private, serve as a vital pathway for generating high-quality evidence and expanding patient access to safe, effective therapies.

00:18:33 Jenn Dawson

As we move into our next episode, we'll shift our focus from academic settings to motivations and dynamics of clinical trials conducted in private practice and industry environments.

00:18:43 Jenn Dawson

Episode 2 explores how efficiency, patient access, and operational flexibility shape these trials and how they complement academic research to broaden therapeutic innovation.

00:18:55 Jenn Dawson

Join us in Episode 2.

00:18:57 Jenn Dawson

It's important to note that the views and information expressed during this podcast do not necessarily represent those of the Pediatric Dermatology Research Alliance or the program guests.

00:19:07 Jenn Dawson

The purpose of this podcast is to be thought-provoking and to stimulate new ideas, new collaborations, and novel research.

00:19:14 Jenn Dawson

Any reference to medical treatment or disease management is for this purpose only.

00:19:18 Jenn Dawson

It is not an endorsement by PeDRA, and it is not a substitute for medical advice, diagnosis, or treatment.

00:19:24 Jenn Dawson

Any decisions related to medical care should be made in consultation with a qualified healthcare provider.

00:19:30 Jenn Dawson

For a complete list of guest disclosures, please click the link in the episode notes.

00:19:35 Jenn Dawson

This independent medical education program is supported by Insight.

00:19:39 Jenn Dawson

I would also like to take a moment to thank PeDRA Corporate Council members.

00:19:43 Jenn Dawson

Our gold level supporters are Eli Lilly and Sanofi and Regeneron Pharmaceuticals.

00:19:49 Jenn Dawson

Our silver level supporters are AbbVie, Abeona Therapeutics, our Arcutis Biotherapeutics, Chiesi, Insight, Sanofi, and UCB.

00:20:00 Jenn Dawson

And our bronze level supporters are DISC Medicine, Janssen,

00:20:04 Jenn Dawson

and Pfizer.

00:20:06 Jenn Dawson

We so appreciate their shared commitment to PeDRA’s mission as members of the PeDRA Corporate Council.

00:20:12 Jenn Dawson

If you enjoyed this episode, be sure to follow us or subscribe to the PeDRA Pearls Podcast channel wherever you listen so you don't miss future conversations.

00:20:21 Jenn Dawson

To learn more about PeDRA and our work to advance research in pediatric dermatology,

00:20:27 Jenn Dawson

visit PedraResearch.org or follow us on social media @PeDRAResearch.

00:20:34 Jenn Dawson

Until next time, keep listening, learning, and collaborating to make a difference for kids with skin disease.